Simrat Randhawa

EVP R&D Simrat Randhawa sells 26,530 shares ($2.4M) via 10b5-1 plan; retains 4,000 shares + 209,076 in derivatives.

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, executed three separate sales totaling 26,530 shares for $2,404,076.95 at a blended average price of $90.62 on 2026-06-01. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the sales were scheduled rather than discretionary. The insider's non-derivative holdings fall from 30,530 shares to 4,000 shares, representing a reduction of 86.9%, while substantial derivative holdings (209,076 shares across four stock options) remain post-transaction. At the current price of $81.57, the stock trades 15.5% below its 52-week high of $96.50, having declined 6.7% over the past 30 days despite a 31.5% gain over the past 90 days. The company reported revenue of $396,000.00 in the latest quarter, a net loss of $40,834,000.00, and annual revenue growth of -67.4%, with no profitability over its most recent full fiscal year. Prior sales by this insider at DNTH over the last eight months have consistently produced positive subsequent returns: a +10.2% 30-day return on the 2026-03-12 sale and multi-month returns ranging from +9.8% to +39.4% on five trades between November 2025 and March 2026. The scheduled nature of this divestment under a 10b5-1 plan precludes timing-based inference, but the context—significant share reduction paired with retained derivative exposure, severe revenue contraction, and ongoing losses—warrants attention to operational fundamentals.

EVP Head of R&D Randhawa sells all 33,830 shares of DNTH at $81.48; complete exit at 10.4% above current price

Randhawa, EVP and Head of R&D, liquidated his entire 33,830-share position in Dianthus Therapeutics at $81.48 on 2026-03-12, exiting a complete holding with no shares remaining. The sale price of $81.48 sits 10.4% above the current price of $77.86, yet significantly below the 52-week high of $86.92. Notably, at DNTH specifically, Randhawa's prior four sales (all in November 2025) generated positive 30-day and 90-day returns—stock rose after each sale—with a 0% well-timed rate at the 90-day mark, indicating consistently poor timing in predicting downturns at this ticker. Against a company background of declining revenue (-67.4% year-over-year), minimal quarterly revenue of $396,000.00, and a net loss of $-36,765,000.00, the complete liquidation by the R&D leader warrants attention as a signal of insider behavior in an unprofitable biotech context, though the prior track record at this specific ticker offers no evidence of predictive accuracy regarding subsequent price movement.

EVP Randhawa sells 196,538 shares ($7.4M) across 4 transactions at $35.80–$38.14 on Nov 13–14, reducing holdings to 4,000 shares (-98.0%).

Randhawa Simrat, Head of R&D, executed 4 separate sales totaling 196,538 shares for $7,379,887.46, leaving only 4,000 shares post-transaction—a near-complete exit from her position. The sales occurred at prices ranging from $35.80 to $38.14, with a blended average of $37.55, at a time when the stock trades at $40.85 and sits at its 52-week high (+0.0% from the peak). His prior trading history at DNTH shows two buys in September 2023 that delivered negative 90-day returns (−5.8% and −5.8% at 30 days, −33.7% and −42.4% at 90 days), indicating a pattern of unfavorable entry timing at this ticker. The company is unprofitable, with a net loss of $-36,765,000.00 in its most recent full fiscal year, while revenue stands at $396,000.00 in the latest quarter despite strong annual growth of +120.6%. The scale and timing of this divestiture—liquidating nearly all shares while the stock reaches its 52-week high—merits scrutiny regarding the insider's conviction in the company's near-term trajectory.